Comparative Pharmacology
Head-to-head clinical analysis: PIPERAZINE CITRATE versus VANSIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIPERAZINE CITRATE versus VANSIL.
PIPERAZINE CITRATE vs VANSIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
Vansil (oxamniquine) is an antischistosomal agent that increases calcium permeability in susceptible schistosomes, leading to muscle contraction, paralysis, and eventual death of the parasite. It is specifically active against Schistosoma mansoni.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
20 mg/kg orally twice daily for 1 day (maximum single dose: 1 g).
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 85-105 hours in patients with normal renal function, allowing once-daily dosing; prolonged in renal impairment
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Primarily renal (70-80% as unchanged drug) with minor biliary/fecal elimination (15-20%) and hepatic metabolism (10-15%)
Category C
Category C
Anthelmintic
Anthelmintic